A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-21 and is reviewed periodically as new material appears.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
During this period, the average EBITDA/sales and EBIT/sales ratios of representative companies were 15% and 71⁄2%, respectively; during the boom, they were 20% and 10–13% respectively and, during the bust, they were 10% and 5% respectively. The differences within these ranges reflects the volatility of the industry's profitability. All in all, the average Western fine-chemical firms have been making a return below the cost of capital — they are not reinvestment grade.
=== Hydrogel cross-linked with polyacrylamide === Marketed as Bulkamid, this material is a synthetic non-particulate hydrogel composed of water and cross-linked polyacrylamide (2.5%). The size of the molecules is large which makes it resistant to migration. Since it is a non particulate homogeneous hydrogel, it is thought to retain elasticity and does not lead to hard tissue fibrosis or cause other significant reaction in the surrounding tissues. It is non-resorbable and non allergenic. In plastic surgery it is marketed as Aquamid. In one publication where it was used for FI, intersphincteric injection site was used via the intersphincteric route. This material has not achieved widespread use.
=== Family history === A family history of end-stage renal disease with hearing impairment is suggestive of Alport syndrome, but other conditions can cause this combination of abnormalities. Most can be distinguished by clinical features. The finding of haematuria in relatives is suggestive. While X-linked inheritance is the most common pattern, genetic testing is revealing that atypical presentations may be more common than currently thought.
China's Atomic Energy Authority rates the China Experimental Fast Reactor at 65 MW thermal and 20 MW electrical. It first reached criticality in 2010 and supplied electricity to the grid in 2011. China initiated a research and development project in thorium molten-salt thermal breeder-reactor technology (liquid fluoride thorium reactor), formally announced at the Chinese Academy of Sciences annual conference in 2011. Its ultimate target was to investigate and develop a thorium-based molten salt nuclear system over about 20 years. In November 2025, the Chinese Academy of Sciences reported thorium-to-uranium fuel conversion in an experimental molten-salt reactor built by its Shanghai Institute of Applied Physics. The institute described a goal of demonstrating a 100-megawatt project by 2035.
Russell and Norvig agree with Turing that intelligence must be defined in terms of external behaviour, not internal structure. However, they are critical that the test requires the machine to imitate humans. "Aeronautical engineering texts", they wrote, "do not define the goal of their field as making 'machines that fly so exactly like pigeons that they can fool other pigeons.'" AI founder John McCarthy agreed, writing that "Artificial intelligence is not, by definition, simulation of human intelligence". McCarthy defines intelligence as "the computational part of the ability to achieve goals in the world". Another AI founder, Marvin Minsky, similarly describes it as "the ability to solve hard problems". Artificial Intelligence: A Modern Approach defines it as the study of agents that perceive their environment and take actions that maximise their chances of achieving defined goals. The many differing definitions of AI have been critically analysed. During the 2020s AI boom, the term has been used as a marketing buzzword to promote products and services which do not use AI.
Sources: en.wikipedia.org
Magoulick & Marshall (2026) interpret lack of dispersal of pronghorns into South America during the Great American Interchange as most likely linked to lack to suitable climatic conditions in potential dispersal corridors. A study on the limb bone histology and life history of Ampelomeryx ginsburgi is published by Viladot et al. (2026). Quaranta et al. (2026) reconstruct the biogeographical history of giraffids on the basis of the Miocene to Holocene fossil record. Al Riaydh et al. (2026) study the assemblage of giraffid astragali from upper Miocene-Pliocene As-Sahabi deposits (Libya), and identify fossil material of two species of Samotherium (S. major and S. boissieri) that likely differed in habitat preferences. Tsatsalis & van der Geer (2026) reconstruct life histories of Pleistocene Axis lydekkeri and Duboisia santeng from Java (Indonesia), reporting evidence of high juvenile mortality and evidence of survival after senescence. Evidence from the study of the isotopic composition of tooth enamel of deer and Alpine ibex from the Melitzia Cave (Greece), indicative of presence of a Late Pleistocene refugium in the Mani Peninsula, is presented by Tzortzi et al. (2026). Evidence of a flexible dietary niche of reindeer living in Europe from Marine Isotope Stage 5a to Marine Isotope Stage 2 is presented by Hemmingham, Pappa & Schreve (2026). New fossil material of Sinomegaceros ordosianus, providing new information on the morphology of members of this species, is described from the Pleistocene strata from the Yitong River basin (China) by Zhang & Wang (2026).
=== Mechanism === The components of the ear involved in cauliflower ear are the outer skin, the perichondrium, and the cartilage. The outer ear skin is tightly adherent to the perichondrium because there is almost no subcutaneous fat on the anterior of the ear. This leaves the perichondrium relatively exposed to damage from direct trauma and shear forces, created by a force pushing across the ear like a punch, and increasing the risk of hematoma formation. In an auricular hematoma, blood accumulates between the perichondrium and cartilage. The hematoma mechanically obstructs blood flow from the perichondrium to the avascular cartilage. This lack of perfusion puts the cartilage at risk for becoming necrotic and/or infected. If left untreated, disorganized fibrosis and cartilage formation will occur around the aforementioned cartilaginous components. Consequently, the concave pinna fills with disorganized connective tissue. The cartilage then deforms and kinks, resulting in the distinctive appearance somewhat resembling a cauliflower. Rapid evacuation of the hematoma restores close contact between the cartilage and perichondrium, thereby reducing the likelihood of deformity by minimizing the ischemia that would otherwise result from a remaining hematoma. Auricular hematoma most often occurs in the potential space between the helix and the antihelix (scapha) and extends anteriorly into the fossa triangularis. Less frequently, the hematoma may form in the concha or the area in and around the external auditory meatus.
Guanidines are a group of organic compounds sharing a common functional group with the general structure (R1R2N)(R3R4N)C=N−R5. The central bond within this group is that of an imine, and the group is related structurally to amidines and ureas. Examples of guanidines are arginine, triazabicyclodecene, saxitoxin, and creatine. One technique for persubstituted guanidine synthesis converts a urea to the diaminodichloride with phosgene and then uses the product to alkylate another amine. Galegine is an isoamylene guanidine.
=== Autoimmune diseases === Problems posed by the differences in the human and rodent immune systems have been overcome using a few strategies, so as to enable researchers to study autoimmune disorders using humanized models. As a result, the use of humanized mouse models has extended to various areas of immunology and disease research. For instance, humanized mice have been utilized to study human-tropic pathogens, liver cancer models, and the comparison of mouse models to human diseases NSG mice engrafted with PBMCs and administered with myelin antigens in Freund's adjuvant, and antigen-pulsed autologous dendritic cells have been used to study multiple sclerosis. Similarly, NSG mice engrafted with hematopoietic stem cells and administered with pristane have been used for studying lupus erythematosus. Furthermore, NOG mice engrafted with PBMCs has been used to study mechanisms of allografts rejection in vivo. The development of humanized mouse models has significantly advanced the study of autoimmune disorders and various areas of immunology and disease research. These models have provided a platform for investigating human diseases, immune responses, and therapeutic interventions, bridging the gap between human and rodent immune systems and offering valuable insights into disease pathogenesis and potential therapeutic strategies.
Sources: en.wikipedia.org
==== Cost, coverage and supply ==== In 2023, Ozempic, the semaglutide injection used for type 2 diabetes treatment, had list price of one-month supply of $936 in the US, $169 in Japan, $147 in Canada, $144 in Switzerland, $103 in Germany and the Netherlands, $96 in Sweden, $93 in the UK, and $87 in Australia; France had the lowest price at $83. High demand caused worldwide supply shortages of semaglutide in 2023; new UK prescriptions were not issued during the shortage. Novo Nordisk revealed in April 2024, that to meet the enormous demand for semaglutide, it was running its production facilities 24/7; it had budgeted $6 billion in 2024 to expand its crowded and congested facilities; and it had hired over 10,000 new employees in 2023 alone.
=== Post-translational modifications === ECD-MS fragments can retain posttranslational modifications such as carboxylation, phosphorylation and O-glycosylation. ECD has the potential to do the top-down characterization of the major types of posttranslational modifications in proteins. It successfully cleaved 87 of 208 backbone bonds and provided the first direct characterization of a phosphoprotein, bovine β casein, simultaneously restricting the location of five phosphorylation sites. It has advantages over CAD to measure the degree of phosphorylation with a minimum number of losses of phosphates and for phosphopeptide/phosphoprotein mapping, which makes ECD a superior technique.
He headed the School of Pharmacy at Manchester on two occasions, 1988-1991 and 1998-2001, periods involving the move to clinical pharmacy and moving Pharmacy from the Faculty of Science and Engineering to the Faculty of Medicine, in recognition of the changing professional role of pharmacists from fabricator to health care advisor on medicines. Rowland has trained 90 Ph.D. students and scientists from a variety of disciplines. He also established ongoing annual postgraduate workshops in basic pharmacokinetics with Tomas Tozer (1977), and in advanced methods in pharmacokinetics and pharmacodynamics with Lewis Sheiner (1981). Rowland was president of EUFEPS (European Federation for Pharmaceutical Sciences, 1996-1999), and a Vice-President of FIP (International Pharmaceutical Federation, 2001-2009).
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.